Gland or Fat? How Clinicians Actually Tell Gynecomastia From Pseudogynecomastia, and Why It Changes Everything

A man standing in front of a mirror cannot reliably tell whether his chest fullness is glandular tissue or fat. That single fact explains a large share of failed diet attempts, disappointing liposuction results, and unnecessary anxiety. True gynecomastia is a proliferation of breast gland tissue, driven by the ratio of estrogen to androgen activity at the breast. Pseudogynecomastia is fat accumulation in the same region, driven by overall adiposity. The distinction matters because gland does not respond to weight loss or liposuction alone, and fat does not respond to gland excision. Two conditions, two mechanisms, two treatment paths.

The first diagnostic step is not imaging. It is a physical exam that clinicians have used for decades, sometimes called the pinch test. The examiner has the patient lie flat, then places a thumb and forefinger on either side of the breast and slowly brings them together toward the nipple. Glandular tissue feels like a firm, rubbery, mobile disc located directly beneath the areola, often with a distinct edge you can trace. Fat, by contrast, offers no discrete disc. The fingers meet gradually through soft, uniform tissue with no clear boundary. In a man with mixed presentation, which is common, the examiner feels a central firm disc surrounded by softer fat extending toward the armpit and lower chest.

Why does gland sit under the areola specifically? Male breast tissue is rudimentary but real. Every man has a small ductal system concentrated in the subareolar region. When estrogen signaling rises relative to androgen signaling, whether from puberty, aging, weight gain increasing aromatase activity in fat tissue, certain medications, anabolic steroid use, or endocrine disorders, those ducts proliferate and the surrounding stroma thickens. The result is that firm central disc. Fat, meanwhile, distributes according to general adipose patterns and has no anatomical reason to concentrate under the areola.

Imaging enters the picture in specific situations. Ultrasound is the usual second step when the exam is ambiguous, when the tissue is unilateral, when there is pain out of proportion to the exam, or when there is any feature that raises concern, such as a hard fixed mass, nipple discharge, skin changes, or enlarged lymph nodes. On ultrasound, gynecomastia typically appears as hypoechoic tissue fanning out from the nipple, while pseudogynecomastia shows only subcutaneous fat. Male breast cancer is rare, roughly one percent of all breast cancers, but it exists, and unilateral firm masses in older men deserve evaluation rather than assumption.

Blood work is reserved for cases where the history suggests a driver worth finding: rapid onset in an adult, tenderness, testicular symptoms, or medication changes. A typical panel checks testosterone, estradiol, luteinizing hormone, prolactin, thyroid function, and sometimes hCG, since certain tumors secrete it. In pubertal gynecomastia, which affects up to half or more of adolescent boys transiently, extensive workup is usually unnecessary because most cases resolve within one to two years.

Now the treatment consequences. If the diagnosis is pseudogynecomastia, the tissue is metabolically ordinary fat. It responds to caloric deficit, and if a stubborn residual pocket remains at a stable weight, liposuction addresses it well because the cannula removes exactly what is there. If the diagnosis is true or mixed gynecomastia, liposuction alone frequently underdelivers. Standard cannulas struggle to extract dense fibrous gland, which is why many surgeons combine liposuction for the peripheral fat with direct excision of the subareolar disc through a small incision at the areolar border. Skip the excision in a patient with a significant gland component and the central firmness persists, sometimes looking more prominent once the surrounding fat is gone.

Medication has a narrower role than marketing sometimes implies. Selective estrogen receptor modulators such as tamoxifen have evidence for reducing pain and size in early proliferative gynecomastia, generally within the first year of onset, when the tissue is still ductal and stromal rather than fibrotic. Once gland has been present for a year or more, it tends to fibrose, and fibrotic tissue does not meaningfully regress with medication. At that stage, surgery is the reliable option. This timing detail is one of the most practically useful facts in the entire field and one of the least widely known.

A final myth worth flattening: chest exercises do not treat either condition. Building the pectoralis muscle can push existing tissue forward and sometimes makes the contour more noticeable, not less. Muscle sits beneath the fat and gland, and no amount of pressing spot reduces what lies on top of it.

The takeaway is simple. Before pursuing any treatment for male chest fullness, get an actual diagnosis: an exam by someone who knows how a glandular disc feels, ultrasound if anything is atypical, and labs if the history warrants it. The mirror cannot distinguish gland from fat. A trained hand usually can, and the answer determines whether the right tool is a diet, a cannula, a scalpel, or simply time.

Related reading: Treating male love handles and flank fat and Why liposuction cannot flatten every male belly.